Breaking News, Collaborations & Alliances

WuXi Biologics, Sinorda Biomedicine Partner to Advance SND006

Will accelerate development and manufacturing of the innovative bispecific antibody for potential treatment of IBD.

Author Image

By: Charlie Sternberg

Associate Editor

Dr. Chris Chen (right), CEO of WuXi Biologics, and Dr. Pingsheng Hu (left), Chairman and General Manager of Sinorda Biomedicine.

WuXi Biologics, a global Contract Research, Development, and Manufacturing Organization (CRDMO), and Sinorda Biomedicine have jointly announced a strategic collaboration for the development and manufacturing of SND006, a novel bispecific antibody, for the potential treatment of inflammatory bowel disease (IBD) and other autoimmune diseases. Under the agreement, Sinorda Biomedicine will leverage WuXi Biologics’ experience and manufacturing capabilities in biologics development and manufa...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters